Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Intervention not reported
Overall survival1 · Patients with advanced non‐small cell lung cancer
The intervention leads to lower overall survival1 (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival1 · Patients with advanced non‐small cell lung cancer
The intervention showed no clear difference in progression‐free survival1 (low certainty).
1 finding from 1 review
Intervention not reported
One‐year survival rate2 · Patients with advanced non‐small cell lung cancer
The intervention leads to higher one‐year survival rate2 (high certainty).
1 finding from 1 review
Intervention not reported
Objective response rate2 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher objective response rate2 (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life3 · Patients with advanced non‐small cell lung cancer
1 finding from 1 review
Intervention not reported
Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher serious adverse events2,4 (low certainty).
1 finding from 1 review
RR 37.36 [10.66, 130.95]
1 study · 4 participants
Low
Intervention not reported
5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐ year OS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐year PFS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N+ OS · patients with resectable gastric cancer
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T1/2 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T3/4 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N‐ OS · patients with resectable gastric cancer
The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review